WallStSmart

GlucoTrack Inc (GCTK)vsMedtronic PLC (MDT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

MDT leads profitability with a 13.9% profit margin vs 0.0%. GCTK trades at a lower P/E of 0.1x. MDT earns a higher WallStSmart Score of 68/100 (B-).

GCTK

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -34.50

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GCTK.

MDTUndervalued (+6.2%)

Margin of Safety

+6.2%

Fair Value

$94.34

Current Price

$88.64

$5.70 discount

UndervaluedFair: $94.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GCTK2 strengths · Avg: 10.0/10
P/E RatioValuation
0.1x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-0.0110/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$114.23B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

GCTK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.04M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GCTK

The strongest argument for GCTK centers on P/E Ratio, Debt/Equity.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : GCTK

The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

GCTK carries more volatility with a beta of 0.66 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 27/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GlucoTrack Inc

HEALTHCARE · MEDICAL DEVICES · USA

GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?